Clinical Study
Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
Table 1
Patient characteristics.
| | () | No. (%) | | |
| | Age at diagnosis | | | | | Median (range) | 65 (46–77) | | | | T-stage | | | | | T1b | 6 (2.3) | | | | T1c | 89 (33.6) | | | | T2a | 38 (14.3) | | | | T2b | 22 (8.3) | | | | T2c | 29 (10.9) | | | | T3a | 64 (24.2) | | | | T3b | 14 (5.3) | | | | T4 | 3 (1.1) | | | | Gleason score | | | | | ≤6 | 144 (54.3) | | | | 7 | 86 (32.5) | | | | ≥8 | 35 (13.2) | | | | PSA ng/mL | | | | | Median (range) | 10.0 (1.7–158.0) | | | | <10.0 | 127 (47.9) | | | | 10.0–19.9 | 86 (32.5) | | | | ≥20.0 | 52 (19.6) | | |
| | NCCN risk group | | Median PSA
(ng/mL) (range) | Median prostate volume (cc) (range) |
| | Low risk | 63 (23.8) | 6.1 (3.0–9.6) | 31.0 (19.0–90.0) | | Intermediate risk | 95 (35.8) | 11.0 (1.7–20.0) | 40.0 (14.0–113.0) | | High risk | 107 (40.4) | 18.0 (3.6–158.0) | 37.5 (14.0–120.0) | | Smoker | | | | | Yes | 45 (17.0) | | | | No | 212 (80.0) | | | | Unknown | 8 (3.0) | | | | Diabetic | | | | | Yes | 33 (12.5) | | | | No | 230 (86.8) | | | | Unknown | 2 (0.8) | | | | TUR-P | | | | | Yes | 12 (4.5) | | | | No | 251 (94.7) | | | | Unknown | 2 (0.8) | | | | Rectal rod | | | | | Yes | 147 (55.5) | | | | No | 118 (44.5) | | | | GU baseline | | | | | 0 | 122 (46.0) | | | | 1 | 95 (35.8) | | | | 2 | 38 (14.3) | | | | 3 | 9 (3.4) | | | | 4 | 0 (0.0) | | | | Unknown | 1 (0.4) | | | | GI baseline | | | | | 0 | 244 (92.1) | | | | 1 | 15 (5.7) | | | | 2 | 5 (1.9) | | | | 3 | 0 (0.0) | | | | 4 | 0 (0.0) | | | | Unknown | 1 (0.4) | | |
|
|
